ArticleClinical research in cardiology : official journal of the German Cardiac Society2010
Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 192 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
192 citing papers in PubMed, 1 synthesis or guideline pooled it, 460 citations in OpenAlex.
- Galectin-3 and risk of atrial fibrillation: A systematic review and meta-analysis.Journal of clinical laboratory analysis · 2020Pooled it
- Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Trial
- Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial.Cardiovascular therapeutics · 2017Trial
- Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).JACC. Heart failure · 2015Trial
- Plasma galectin 3 and heart failure risk in the Physicians' Health Study.European journal of heart failure · 2014Trial
- Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.Journal of cardiac failure · 2014Trial
- Galectin 3 complements BNP in risk stratification in acute heart failure.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2012Trial
- Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.Circulation. Heart failure · 2012Trial
- Atrial Cardiomyopathy: Pathophysiology, Diagnostic Approaches, and Prognostic Implications-A Narrative Review.Journal of clinical medicine · 2026Review
- Evolving Proteomic Biomarkers in Children with Congenital Heart Defects.Journal of cardiovascular development and disease · 2026Review
- Beyond eGFR and Albuminuria: Biological Pathways and Multiomics in Cardiovascular-Kidney-Metabolic Disease.Kidney international reports · 2026Review
- Myocardial fibrosis and viability: the role of imaging and biomarkers in patients with chronic total occlusion on coronary angiography.Biochemia medica · 2026Review
- Endothelial-to-Mesenchymal Transition Mechanisms in Vascular Remodeling of Pulmonary Hypertension.International journal of molecular sciences · 2026Review
- Subclinical Inflammation in Ischemic Heart Disease and Its Role in the Transition to Heart Failure.Life (Basel, Switzerland) · 2026Review
- Current Advancements in Untargeted Metabolomics Analysis and Testing Driven by Machine Learning: Prospects for Artificial Intelligence in Patient-Centric Healthcare Transformation.Applied biochemistry and biotechnology · 2026Review
- Cardiovascular burden of long coronavirus disease: Clinical challenges and emerging biomarkers.World journal of cardiology · 2026Review
- The Role of Galectin-3 in Atherosclerosis and Its Cardiovascular Complications: An Update.Journal of lipid and atherosclerosis · 2026Review
- Galectin-3 Is Independently Associated With Short-Term Mortality and Identifies Low-Risk Patients With Acute Dyspnea in the Emergency Department: A Retrospective Cohort Study.Biomarker insights · 2026Article
- SALVE: prediction of interorgan communication with transcriptome latent space representation.American journal of physiology. Heart and circulatory physiology · 2025Article
- Galectin-3 and Strain Imaging for Early Heart Failure Prediction After First Myocardial Infarction.International journal of molecular sciences · 2025Article
132 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsBiomarkers are increasingly being used in the management of patients with chronic heart failure (HF). Galectin-3 is a recently developed biomarker associated with fibrosis and inflammation, and it may play a role in cardiac remodeling in HF. We determined its prognostic value in patients with chronic HF. METHODS AND
resultsPatients with chronic HF (New York Heart Association functional class III or IV) who participated in the Deventer-Alkmaar heart failure study were studied. Galectin-3 levels were determined at baseline using a novel optimized enzyme-linked immunosorbent assay. Univariate and multivariate analyses were used to determine the prognostic value of this biomarker. We studied 232 patients; their mean age was 71 +/- 10 years, 72% were male, and 96% were in NYHA class III. During a follow-up period of 6.5 years, 98 patients died. Galectin-3 was a significant predictor of mortality risk after adjustment for age and sex, and severity of HF and renal dysfunction, as assessed by NT-proBNP and estimated glomerular filtration rate, respectively (hazard ratio per standard deviation 1.24, 95% CI 1.03-1.50, P = 0.026).
conclusionPlasma galectin-3 is a novel prognostic marker in patients with chronic HF. Its prognostic value is independent of severity of HF, as assessed by NT-proBNP levels, and it may potentially be used in the management of such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.